Abivax S.A.(ABVX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ABVX Abivax S.A.

休市中 12-05 16:00:00 EST

114.51

+3.87

+3.50%

盘后117.92

+3.41+2.98%

19:56 EST

最高115.12	最低109.10	成交量129.71万
今开109.75	昨收110.64	日振幅5.44%
总市值89.21亿	流通市值48.85亿	总股本7,790万
成交额1.46亿	换手率3.04%	流通股本4,266万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ABVX","market":"US","secType":"STK","nameCN":"Abivax S.A.","latestPrice":114.51,"timestamp":1764968400000,"preClose":110.64,"halted":0,"volume":1297146,"hourTrading":{"tag":"盘后","latestPrice":117.92,"preClose":114.51,"latestTime":"19:56 EST","volume":15868,"amount":1849096.0873,"timestamp":1764982611530},"delay":0,"floatShares":42655700,"shares":77903300,"eps":-3.625474,"marketStatus":"休市中","change":3.87,"latestTime":"12-05 16:00:00 EST","open":109.75,"high":115.12,"low":109.1,"amount":145871456.243616,"amplitude":0.054411,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.625474,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1697774400000,"exchange":"NASDAQ","adjPreClose":110.64,"preHourTrading":{"tag":"盘前","latestPrice":109.63,"preClose":110.64,"latestTime":"09:29 EST","volume":11864,"amount":1299598.5764,"timestamp":1764944971055},"postHourTrading":{"tag":"盘后","latestPrice":117.92,"preClose":114.51,"latestTime":"19:56 EST","volume":15868,"amount":1849096.0873,"timestamp":1764982611530},"volumeRatio":0.8963467167608143,"impliedVol":1.2377,"impliedVolPercentile":0.9636},"requestUrl":"/m/hq/s/ABVX","defaultTab":"news","newsList":[{"id":"2588100965","title":"暴涨1300%后，Abivax的“疯牛叙事”或还未结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2588100965","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588100965?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:38","pubTimestamp":1764837493,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，法国生物技术公司 Abivax年初市值不足 5 亿美元。该研究结果预计将于 2026 年第二季度公布，若成功，Abivax将能够提交该药物的监管审批申请。今年 7 月，Abivax 公司表示，在后期试验中，服用obefazimod的患者在八周后中度至重度活动性溃疡性结肠炎的症状消失。持续的积极临床试验结果将有助于保持这一势头。该公司是 Abivax 的投资方。","market":"sh","thumbnail":"https://static.tigerbbs.com/55eb327f580527889cf30bafa92692ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/55eb327f580527889cf30bafa92692ae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377654.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","ABVX"],"gpt_icon":1},{"id":"2580532767","title":"Abivax涨1.16% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2580532767","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580532767?lang=zh_cn&edition=full","pubTime":"2025-11-04 22:42","pubTimestamp":1762267343,"startTime":"0","endTime":"0","summary":"北京时间2025年11月04日22时42分，Abivax股票出现异动，股价大幅拉升1.16%。截至发稿，该股报100.00美元/股，成交量9.6872万股，换手率0.12%，振幅1.40%。Abivax股票所在的生物技术行业中，整体跌幅为0.55%。其相关个股中，Terns Pharmaceuticals, Inc.、Aurinia Pharmaceuticals Inc、Abpro Holdings, Inc涨幅较大，Artelo Biosciences, Inc.、Abpro Holdings, Inc、Biomx Inc.较为活跃，换手率分别为274.69%、90.90%、66.23%，振幅较大的相关个股有Terns Pharmaceuticals, Inc.、Nuvation Bio Inc.、Verastem, Inc.，振幅分别为20.10%、18.76%、17.47%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110422422494eec99f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110422422494eec99f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ABVX"],"gpt_icon":0},{"id":"2573450963","title":"Abivax的口服溃疡性结肠炎药物3期数据进一步巩固优势：对既往失败患者临床缓解率达34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2573450963","media":"Minhua笔记","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2573450963?lang=zh_cn&edition=full","pubTime":"2025-10-07 17:05","pubTimestamp":1759827948,"startTime":"0","endTime":"0","summary":"Abivax的口服UC候选药物obefazimod在3期ABTECT试验中显示对既往晚期治疗失败的患者安慰剂调整临床缓解率达34%，进一步巩固其竞争优势，估值超65亿美元。之前的临床结果今年夏天，Abivax的口服溃疡性结肠炎候选药物obefazimod的两个晚期研究结果促使其股价飙升。Abivax正在III期ABTECT-1和ABTECT-2试验中研究miR-124增强剂，这两项试验共入组了1272名中重度活动性UC患者。Abivax还报告了从ABTECT-1和ABTECT-2临床试验最新汇总的安全性数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251007170723a6af9a07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251007170723a6af9a07&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABVX","BK4139"],"gpt_icon":0},{"id":"2566595917","title":"Abivax盘中异动 股价大跌5.06%报83.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2566595917","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566595917?lang=zh_cn&edition=full","pubTime":"2025-09-11 22:57","pubTimestamp":1757602641,"startTime":"0","endTime":"0","summary":"北京时间2025年09月11日22时57分，Abivax股票出现波动，股价急速跳水5.06%。截至发稿，该股报83.20美元/股，成交量56.4487万股，换手率0.75%，振幅3.97%。Abivax股票所在的生物技术行业中，整体涨幅为1.01%。公司正在 3 期临床试验中评估其候选药物 obefazimod 用于治疗成人中度至重度活动性溃疡性结肠炎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091122572195261523&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091122572195261523&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABVX","BK4139"],"gpt_icon":0},{"id":"2558691278","title":"Abivax8月11日成交额为4068.67万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558691278","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558691278?lang=zh_cn&edition=full","pubTime":"2025-08-12 09:15","pubTimestamp":1754961321,"startTime":"0","endTime":"0","summary":"美东时间2025年8月11日，Abivax成交额为4068.67万美元，成交额较昨日减少13.12%，当日成交量为58.40万股。Abivax于2025年8月11日跌1.61%，报69.0美元，该股过去5个交易日跌4.26%，年初至今涨842.62%，过去60日涨1031.15%。公司正在 3 期临床试验中评估其候选药物 obefazimod 用于治疗成人中度至重度活动性溃疡性结肠炎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812091536a6e08032&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812091536a6e08032&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABVX","BK4139"],"gpt_icon":1},{"id":"2558503872","title":"Abivax8月8日成交额为4682.88万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558503872","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558503872?lang=zh_cn&edition=full","pubTime":"2025-08-09 09:15","pubTimestamp":1754702123,"startTime":"0","endTime":"0","summary":"美东时间2025年8月8日，Abivax成交额为4682.88万美元，成交额较昨日减少42.14%，当日成交量为66.84万股。Abivax于2025年8月8日涨0.16%，报70.13美元，该股过去5个交易日跌2.53%，年初至今涨858.06%，过去60日涨1061.09%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-08|4682.88万|-42.14%|66.84万|#|2025-08-07|8093.06万|-29.39%|114.54万|#|2025-08-06|1.15亿|76.53%|163.60万|#|2025-08-05|6492.88万|73.34%|92.65万|#|2025-08-04|3745.79万|-58.34%|52.68万|Abivax SA 是一家总部位于法国的临床阶段生物技术公司，专注于开发利用身体自然调节机制来稳定慢性炎症性疾病患者免疫反应的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809091537a6dbdc49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809091537a6dbdc49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABVX","BK4139"],"gpt_icon":0},{"id":"2557458974","title":"Abivax8月6日成交额为1.15亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557458974","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557458974?lang=zh_cn&edition=full","pubTime":"2025-08-07 09:15","pubTimestamp":1754529325,"startTime":"0","endTime":"0","summary":"美东时间2025年8月6日，Abivax成交额为1.15亿美元，成交额较昨日增加76.53%，当日成交量为163.60万股。Abivax于2025年8月6日跌2.57%，报69.09美元，该股过去5个交易日跌2.47%，年初至今涨843.85%，过去60日涨929.66%。公司正在 3 期临床试验中评估其候选药物 obefazimod 用于治疗成人中度至重度活动性溃疡性结肠炎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807091537a6d78cf4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807091537a6d78cf4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ABVX"],"gpt_icon":0},{"id":"2556327908","title":"Abivax盘中异动 快速上涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556327908","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556327908?lang=zh_cn&edition=full","pubTime":"2025-08-01 00:18","pubTimestamp":1753978696,"startTime":"0","endTime":"0","summary":"北京时间2025年08月01日00时18分，Abivax股票出现异动，股价大幅上涨5.06%。截至发稿，该股报74.42美元/股，成交量67.8585万股，换手率0.90%，振幅6.17%。Abivax股票所在的生物技术行业中，整体涨幅为2.87%。公司正在 3 期临床试验中评估其候选药物 obefazimod 用于治疗成人中度至重度活动性溃疡性结肠炎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801001816a46defc5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801001816a46defc5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ABVX"],"gpt_icon":0},{"id":"2555088365","title":"Abivax7月28日成交额为1.15亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555088365","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555088365?lang=zh_cn&edition=full","pubTime":"2025-07-29 09:15","pubTimestamp":1753751726,"startTime":"0","endTime":"0","summary":"美东时间2025年7月28日，Abivax成交额为1.15亿美元，成交额较昨日减少51.49%，当日成交量为172.23万股。Abivax于2025年7月28日涨0.12%，报66.57美元，该股过去5个交易日涨556.51%，年初至今涨809.43%，过去60日涨834.97%。公司正在 3 期临床试验中评估其候选药物 obefazimod 用于治疗成人中度至重度活动性溃疡性结肠炎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729091543a6c6bfed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729091543a6c6bfed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ABVX"],"gpt_icon":1},{"id":"1133444199","title":"盘前 | 特斯拉绩后跌近6%，谷歌绩后涨近4%，名创优品涨近6%，海外市场增长收入28%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133444199","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133444199?lang=zh_cn&edition=full","pubTime":"2025-07-24 20:03","pubTimestamp":1753358604,"startTime":"0","endTime":"0","summary":"$名创优品$盘前涨近6%，港股大涨7%，中国市场收入增长10%，海外市场增长收入28%。预计期内收入达48.5亿元人民币，同比增20%，其中中国市场收入增长10%，海外市场增长收入28%。谷歌绩后盘前上涨近4%，二季度营收同比增长14%至964.3亿美元，并创下历史纪录，每股收益同比增长22%至2.31美元，均超预期。$特斯拉$绩后盘前跌近6%，Q2营收、净利润双位数下滑。能源业务收入下跌7%。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3c94c29cbd6e48dd1763faf2a3863d59","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNSO","GOOG","TSLA","DB","STM","OPEN","AAL","NDAQ","NOW","TMUS","ABVX"],"gpt_icon":1},{"id":"1156915810","title":"异动解读 | 重磅新药临床试验成功，Abivax盘前大涨5.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156915810","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156915810?lang=zh_cn&edition=full","pubTime":"2025-07-24 16:30","pubTimestamp":1753345848,"startTime":"0","endTime":"0","summary":"周四盘前，法国生物科技公司Abivax S.A.股价大涨5.54%，延续了此前的强劲涨势。这一涨幅主要源于该公司近期公布的突破性临床试验结果。Abivax宣布，其用于治疗中度至重度活动性溃疡性结肠炎的候选药物obefazimod在两项关键性III期临床试验中均达到主要终点。试验结果显示，obefazimod在8周诱导期内，相较于安慰剂组显著提高了患者的临床缓解率。受此利好消息影响，Abivax股价在过去几个交易日内持续上涨。今日盘前的5.54%涨幅显示，市场对Abivax的发展前景仍保持乐观态度。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"dcc54a12bb9d1d1308c82fe12f0e51e6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABVX"],"gpt_icon":1},{"id":"1195846412","title":"异动解读 | Abivax股价盘前再涨5.54%，新药临床试验利好持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1195846412","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195846412?lang=zh_cn&edition=full","pubTime":"2025-07-24 16:30","pubTimestamp":1753345831,"startTime":"0","endTime":"0","summary":"法国生物技术公司Abivax股价在周四盘前继续攀升，涨幅达5.54%。这一涨势是对该公司此前公布的重大临床试验结果的持续反应。本周二，Abivax宣布其用于治疗溃疡性结肠炎的口服小分子药物obefazimod在两项关键性III期临床试验中达到主要终点。Abivax计划在2026年下半年向美国FDA提交新药申请。这一积极预期持续推动Abivax股价上涨，而今日盘前的涨幅反映了投资者对公司前景的持续看好。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"dcc54a12bb9d1d1308c82fe12f0e51e6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABVX"],"gpt_icon":1},{"id":"1125427368","title":"盘前异动 | 特斯拉绩后盘前跌近6%，Q2营收、净利润双位数下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=1125427368","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125427368?lang=zh_cn&edition=full","pubTime":"2025-07-24 16:10","pubTimestamp":1753344600,"startTime":"0","endTime":"0","summary":"期内，软件收入增长约10%至73.9亿美元，毛利率为83.9%，略低于预期的84%。特斯拉绩后盘前跌近6%，Q2营收、净利润双位数下滑消息面上，在汽车销量持续下滑的情况下，特斯拉的净利润进一步下滑，第二季度净利润下跌16%至11.72亿美元。能源业务收入下跌7%。特斯拉表示，其营收和盈利能力的下降是由于销量下降和监管信用积分的减少。特斯拉表示，该公司已于6月开始生产首批平价车型，并预计今年下半年将实现量产。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6b21df534720d4af5cf1fe913b70ee7e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX","IBM","TSLA","TMUS"],"gpt_icon":0},{"id":"2553308274","title":"一夜暴涨465%！FIC药物炸出新时代→","url":"https://stock-news.laohu8.com/highlight/detail?id=2553308274","media":"谈思生物","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553308274?lang=zh_cn&edition=full","pubTime":"2025-07-24 15:00","pubTimestamp":1753340429,"startTime":"0","endTime":"0","summary":"受临床数据刺激，Abivax盘后股价瞬间飙涨465%，公司市值由6.34亿美元蹿升至约35.82亿美元。其次，是FIC优势。鉴于全新的作用途径，ABX464将为那些，其他机制药物治疗无效或不耐受的患者提供新的治疗选择。ABTECT研究是目前最大规模的UC三期临床试验之一，30个月内在36个国家600多个临床中心共1275名患者入组，并纳入了最大比例、对JAK抑制剂响应不足的患者。二是ABX464潜力巨大，除了UC，Abivax还相继为其开展了CD单药治疗以及UC联合治疗2大适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724151529a460b07b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724151529a460b07b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABVX","BK4139"],"gpt_icon":0},{"id":"2553522150","title":"新药数据惊艳，美股Abivax暴涨586%，能否打破\"烧钱魔咒\"？","url":"https://stock-news.laohu8.com/highlight/detail?id=2553522150","media":"腾讯自选股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553522150?lang=zh_cn&edition=full","pubTime":"2025-07-24 08:37","pubTimestamp":1753317439,"startTime":"0","endTime":"0","summary":"美东时间7月23日，美股生物技术公司Abivax股价盘初一度暴涨超596%，最终收涨586%，最新市值43.48亿美元。消息面上，Abivax宣布，其首创新型口服miR-124增强剂Obefazimod在中度至重度溃疡性结肠炎的ABTECT 8周诱导试验中取得积极的III期结果。单押miRNA疗法2023年6月份，Abivax递交的obefazimod临床试验申请获CDE受理。不过，药物正式获批上市前，Abivaxs是否能凭借单一候选药物冲出重围仍未可知。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724082621971acd29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724082621971acd29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABVX","BK4139","IBD"],"gpt_icon":1},{"id":"1108137418","title":"异动解读 | 突破性研究结果公布，Abivax股价夜盘暴涨5.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=1108137418","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108137418?lang=zh_cn&edition=full","pubTime":"2025-07-24 08:02","pubTimestamp":1753315362,"startTime":"0","endTime":"0","summary":"7月23日夜盘，法国生物技术公司Abivax股价大涨5.67%，引发市场广泛关注。这一显著涨幅源于该公司公布了其核心药物obefazimod在治疗溃疡性结肠炎方面取得的突破性临床试验结果。根据Abivax发布的公告，obefazimod在针对中度至重度活动性溃疡性结肠炎的ABTECT III期临床试验中取得了积极成果。试验结果显示，在8周诱导期内，obefazimod在实现临床缓解方面明显优于安慰剂。这一突破性进展不仅为溃疡性结肠炎患者带来新的治疗希望，也大大提升了投资者对Abivax前景的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABVX"],"gpt_icon":1},{"id":"1128758434","title":"Abivax飙升至580%，其口服新药 Obefazimod 在溃疡性结肠炎 III 期诱导试验中取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1128758434","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128758434?lang=zh_cn&edition=full","pubTime":"2025-07-23 22:07","pubTimestamp":1753279640,"startTime":"0","endTime":"0","summary":"7月23日（周三），美股盘中Abivax飙升至580%，其口服新药 Obefazimod 在溃疡性结肠炎 III 期诱导试验中取得积极结果，并计划向 FDA 提交申请。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"dcc54a12bb9d1d1308c82fe12f0e51e6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"gpt_icon":0},{"id":"1123514331","title":"异动解读 | 重大突破！Abivax新药临床试验成功，股价盘中暴涨547%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123514331","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123514331?lang=zh_cn&edition=full","pubTime":"2025-07-23 21:35","pubTimestamp":1753277750,"startTime":"0","endTime":"0","summary":"周三盘中，法国生物技术公司Abivax S.A.股价惊人暴涨547%，引发市场轰动。这一戏剧性涨幅背后，是该公司在溃疡性结肠炎治疗领域取得的重大突破。据悉，Abivax的口服溃疡性结肠炎新药obefazimod在两项大型三期临床试验中取得了积极结果。这一突破性进展不仅为溃疡性结肠炎患者带来新的治疗希望，也极大地提升了投资者对Abivax前景的信心。然而，随着obefazimod的成功，公司的融资能力有望大幅提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"dcc54a12bb9d1d1308c82fe12f0e51e6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABVX"],"gpt_icon":0},{"id":"1161750940","title":"开盘 | 三大指数高开，Abivax飙升超550%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161750940","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161750940?lang=zh_cn&edition=full","pubTime":"2025-07-23 21:31","pubTimestamp":1753277514,"startTime":"0","endTime":"0","summary":"7月23日，三大指数高开，道指涨0.36%，标普500指数涨0.34%，纳指涨0.34%。Abivax飙升超550%中概股普涨，小马智行涨5%，万国数据涨4%，蔚来涨3%，小牛电动涨2%。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"dcc54a12bb9d1d1308c82fe12f0e51e6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548",".DJI","BK4531","BK4585","BK4099",".SPX","BK4116","BK4555","LU0052750758.USD","NIU.AU","PONY","BK4534","NIO.SI","NIU",".IXIC","BK4529","BK4563","GDS","ABVX","LU0320764599.SGD","NIO","BK4526","BK4588","BK4614"],"gpt_icon":0},{"id":"1191921961","title":"异动解读 | Abivax盘前暴涨405.70%，溃疡性结肠炎新药三期临床试验结果亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=1191921961","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191921961?lang=zh_cn&edition=full","pubTime":"2025-07-23 16:10","pubTimestamp":1753258247,"startTime":"0","endTime":"0","summary":"法国生物技术公司Abivax S.A.今日盘前股价大涨405.70%，引起市场广泛关注。这一惊人涨幅主要源于该公司最新公布的重磅消息。据悉，Abivax的口服溃疡性结肠炎治疗新药obefazimod在两项大型三期临床研究中取得了突破性进展。Abivax表示，obefazimod的安全性特征与早期试验结果一致，没有出现新的安全问题。这一重大突破不仅为溃疡性结肠炎患者带来了新的治疗希望，也大大提升了投资者对Abivax未来发展前景的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"195af9462123c6ace4455f7e996529a0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABVX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abivax.com","stockEarnings":[{"period":"1week","weight":-0.0827},{"period":"1month","weight":0.1496},{"period":"3month","weight":0.3008},{"period":"6month","weight":12.9817},{"period":"1year","weight":12.7467},{"period":"ytd","weight":14.6434}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Abivax Sa是一家于2013年12月4日根据法国法律注册成立。该公司是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来调节慢性炎症性疾病患者免疫反应的疗法。该公司目前正在3期临床试验中评估主要候选药物奥贝法兹莫德，用于治疗成人中度至重度活动性溃疡性结肠炎。","exchange":"NASDAQ","name":"Abivax S.A.","nameEN":"Abivax S.A."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Abivax S.A.(ABVX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Abivax S.A.(ABVX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Abivax S.A.,ABVX,Abivax S.A.股票,Abivax S.A.股票老虎,Abivax S.A.股票老虎国际,Abivax S.A.行情,Abivax S.A.股票行情,Abivax S.A.股价,Abivax S.A.股市,Abivax S.A.股票价格,Abivax S.A.股票交易,Abivax S.A.股票购买,Abivax S.A.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Abivax S.A.(ABVX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Abivax S.A.(ABVX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}